33 results about "Sulfanyl" patented technology

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-alpha converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-alpha from membrane bound TNF-alpha precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-alpha converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formulawherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R1 and R4 are defined herein.

Organic dyes and photoelectric conversion devices are provided. The Organic dye has the structure represented by formula (I), wherein, n is an integral of 2-11; the plurality of X is independent and elected from the group consisting of

and combinations thereof; R, R¹, and R² comprise hydrogen, halogen, C_1-18 alkyl group, C_1-18 alkoxy group, C_3-18 heteroalkyl group, C_3-20 aryl group, C_3-20 heteroaryl group, C_3-20 cycloaliphatic group or C_3-20 cycloalkyl group, or R¹ is connected to R² to form a ring having 5-14 members; R³ comprise hydrogen, halogen, nitro group, amino group, C_1-18 alkyl group, C_1-18 alkoxy group, C_1-18 sulfanyl group, C_3-18 heteroalkyl group, C_3-20 aryl group, C_3-20 heteroaryl group, C_3-20 cycloaliphatic group or C_3-20 cycloalkyl group; and Z is hydrogen, alkali metal, or quaternary ammonium salt.

A metal paste comprising a mixture consisting of: metal colloidal particles, which consist of particles consisting of one or more metals or metal oxides and a protective agent for protecting the particles; and organic metallic compounds. The metal paste preferably comprising a mixture consisting of: metal colloidal particles comprising, as a protective agent, a compound having an amino group, sulfanyl group, sulfide-type sulfanediyl group, hydroxy group, or ether-type oxy group; and organic metallic compounds such as mercaptan metallic compounds or sulfide metallic compounds of α-pinene, α-terpinenol, or isobornyl acetate, abietic acid metallic compounds, neodecanoic acid metallic compounds, 2-ethylhexanoic acid metallic compounds, naphthenic acid metallic compounds, or decanoic acid metallic compounds.

The invention discloses a preparation method of high-purity vortioxetine hydrobromide. The method comprises the following steps: firstly, synthesizing 2-(2,4-dimethyl phenyl sulfanyl) chlorobenzene from 2-chlorophenol and 2,4-dimethylbenzenethiol; then, adding di(dibenzylideneacetone)palladium, 1,1'-binaphthyl-2,2'-bis(diphenyl phosphine), sodium tert-butoxide, and methylbenzene into a reaction bottle to mix, and adding other materials so as to prepare vortioxetine; and dissolving the prepared vortioxetine by using 14-16 times of ethyl acetate, so that a vortioxetine hydrobromide coarse product is obtained; and finally, purifying the coarse product so as to obtain a vortioxetine hydrobromide fine-product. The method disclosed by the invention is easily-obtained in raw materials, mild in process reaction conditions, high in product yield, high in product purity, and convenient for industrial production. Prepared vortioxetine hydrobromide is white crystalline powder, and the purity is more than 99.5%.

The invention discloses a dual-slurry ammonization granulation compound fertilizer production technology, which is characterized by high nitrogen content and adjustable available nutrients. The technology comprises the following steps: 1, carrying out secondary dechlorination at low temperature; 2, dissolving phosphorus and mixing slurries; 3, cooling and absorbing; 4, melting and dissolving urea; 5, aminating and granulating; 6, drying and cooling; 7, screening and smashing; and 8, packaging. By using the invention, nitrogen content of sulfanyl compound fertilizers rises to 25% from 13%, recycle ratio reduces to 20-30% from 40-50%, yield of single-pass granulation in a granulator is greatly improved, dechlorination time is shortened to 1h from over 2h by adopting the secondary dechlorination technology, the dechlorination is thorough, and the production efficiency is greatly improved.

The invention is directed toward non-wild-type organophosphorus acid anhydrolases having three site mutations, method of production, and method of use to effectively degrade toxic chemical compounds such as (Ethyl({2-[bis(propan-2-yl)amino]ethyl}sulfanyl)(methyl)phosphinate (“VX”).

The invention provides a reactive dye at formula(I)with sulfanyls and beta-sulfate radical ethyl sulphonyls; wherein the definitions of D,R,R1,R2,R3,R4,Q, x and y are detailed in the specification. The reactive dye is of high solubility and high alkali solubility to cellulose base fibre when being used to dye cellulose base fibre and is easy to wash with water; therefore, the reactive dye is applicable in cold pressure dyeing, continuous dyeing, printing and dyeing, and digital printing.

Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-alpha converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-alpha from membrane bound TNF-alpha precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-alpha converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection having the formula wherein R2 and R3 form a heterocyclic ring and A is S, S(O), or S(O)2, and R1 and R4 are defined herein.

The invention belongs to the field of fine chemical engineering, and relates to a method for preparing N-(substituent) benzothiazine-4-ketone without metal participation. Comprising the following steps: sequentially adding N-(substituted)-2-sulfur alkyl benzamide, 1-chloromethyl-4-fluoro-1, 4-diazabicyclo [2.2. 2] octane bis (tetrafluoroborate) salt, sodium iodide and hydroiodic acid into a sealed tube containing a reaction solvent acetonitrile, heating, violently stirring and reacting to obtain the N-(substituted) benzothiazine-4-ketone. The sulfanyl group in the reaction substrate is subjected to C-S bond breakage firstly, then the chloromethyl group in the additive is transferred into the substrate, construction of C-S and C-N is achieved at the same time, and construction of the benzothiazine-4-ketone is achieved. The method has the characteristics of greenness and high efficiency.

The invention provides a functionalized zirconium-based metal organic cage as well as a preparation method and application thereof. The preparation method of the functionalized zirconium-based metal organic cage comprises the following steps: S1, dissolving (S, S)-2, 5-bis-(2-hydroxypropyl sulfanyl)-terephthalic acid and zircon salt in an organic solvent to obtain a mixture; s2, the mixture is subjected to a reaction through a solvothermal method, and a reaction mixture is obtained; s3, the reaction mixture is cooled, crystallized, washed and subjected to solvent exchange, and the functionalized zirconium-based metal organic cage is obtained. The functionalized zirconium-based metal organic cage is simple in preparation method, good in stability, high in detection efficiency, high in sensitivity and strong in anti-interference performance, can realize specific recognition of various environmental pollutants including sulfonamides, nitrofurans and toxic heavy metals under different concentrations, and has good universality.

The present invention relates to Pyridin-2-yl sulfanyl acid ester compounds having antiinflammatory properties. The present invention particularly relates to novel anti-inflammatory heterocyclic acid esters of Pyridin-2-yl sulfanyl having the structure of general formula 1 which have been screened for their antiinflammatory activity with respect to inhibition of adhesion of neutrophils, isolated from human peripheral blood, onto the surface of human umbilical vein endothelial cells (HU-VEC) as a result of inhibition of the cytokine-stimulated expression of cell adhesion molecule ICAM-1. The compound RS—Z, 3-(Pyridin-2-yl sulfanyl)-propionic acid pentyl ester (structure 1a, R₁=H, R₂=H, R₃=CH2-COOC5H₁₁) was found to be most effective for ICAM-1 and neutrophil adhesion inhibition and was found to effectively alleviate inflammation mediated by excessive leukocyte infiltration leading to inflammatory disorders or like conditions, such as acute lung injury and acute respiratory distress syndrome in mice.

An alkyltin compound of specified formula which has utility as an excellent stabilizer for a halogen-containing resin. The alkyltin compound has from 1-3 terminal thiol groups.

The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2[2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2θ±0.2° 2θ (CuKα radiation)) at 5.5°, 14.8°, 16.7° and 20.0° and processes for obtaining the same.

The invention relates to a method for producing 4-pentafluoride-sulfanyl-benzoylguanidines of formula (I) wherein groups from R1 to R4 correspond to meanings given in claims. The compounds of the formula (I) constitute NHE1 inhibitors and can be used for curing cardiovascular diseases.

A novel process for the preparation of a sodium salt of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methyl-ethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid, comprising: a) reacting a compound of Formula 1 with methanesulfonyl chloride in the presence of a tertiary amine to yield a crude solution of a compound of Formula 2; b) filtering the crude solution of compound of Formula 2 obtained in a) to remove solid amine hydrochloride, reacting the filtrate without isolation or further purification with a compound of Formula 3, and isolating 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid; c) reacting the 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid isolated in b) with tert-butylamine to yield a compound of formula 4; d) isolating and purifying the compound of formula 4; and e) converting the compound of formula 4 to a compound of formula 5.